Table 4.

Prevalence of Resistance-Associated Mutations Associated with Entry Inhibitors in Both Cohorts^a

	Observed prevalence for each resistance mutation (%)			Comparison of prevalence between cohorts, pb
	Handema,c2000 (N = 25)	Cohort A, 1998–2002 (N = 26)	Cohort B, 2005 (N = 79)	Handemacto Cohort A	Handemacto Cohort B	Cohort A to Cohort B	Complete resistance	Partial resistance
Maraviroc11
A316T	68	80.7	64.5	0.3487	0.8136	0.1487	−	+
I323V	4	0	3.8	0.4902	1.0000	0.5727	−	+
A316T/I323Va	4	0	3.8	0.4902	1.0000	0.5727	+	−
Vicriviroc12,22
K305R12,22	4	7.7	6.33	1.0000	1.0000	1.0000	−	+
S306P22	0	0	0	N.O.d	N.O.	N.O.	−	+
R315Q12	100	100	98.7	N.O.	1.0000	0.5727	−	+
F318I22	0	0	0	N.O.	N.O.	N.O.	−	+
T320R22	4	0	0	0.4902	0.2404	N.O.	−	+
G321E22	0	3.8	1.26	1.0000	1.0000	0.4357	−	+
K305R, R315Q	4	7.7	5.06	1.0000	1.0000	1.0000	−	+
R315Q, T320R	4	0	0	0.4902	0.2404	N.O.	−	+
K305R, T320R	4	0	0	0.4902	0.2404	N.O.	−	+
K305R, R315Q	0	0	0	N.O.	N.O.	N.O.	−	+
T320R
R315Q, G321E	0	3.8	1.26	1.0000	1.0000	0.4357	−	+
Maraviroc + vicriviroc
A316T + K305R	4	3.8	1.26	1.0000	0.5657	1.0000	−	+
R315Q
A316T + R315Q	68	80.7	58.22	0.3487	0.8116	0.1464	−	+
A316T/I323V +	4	0	3.8	0.4902	1.0000	0.5727	+/−	+/−
R315Q
A316T + R315Q	0	3.8	1.26	1.0000	1.0000	0.4357	−	+
G321E

^aMost of these mutations confer partial resistance; only A316T/I323V has been demonstrated to confer complete resistance to maraviroc.

^bp values from the Fisher's exact test were used to compare the prevalence of mutations between cohorts.

^cHandema et al.⁸

^dN.O., no observations.